Our inter-institutional research team developed RS-D7, a novel NMDAR modulator/DAO inhibitor as a drug candidate for the treatment of ataxia/MSA. Based upon the core symptoms, we designedapplied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the effectiveness of RS-D7our functional assays. RS-D7 offers multi-symptomatic relief.

The present technology provides a method for diagnosing Alzheimer＇s disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer＇s disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer＇s disease.